Biomarkers in Neuropsychiatry最新文献

筛选
英文 中文
Fatty acids as potential biomarkers of stearoyl-CoA desaturase inhibition: Variation in healthy subjects and Parkinson's disease patients 脂肪酸作为硬脂酰辅酶a去饱和酶抑制的潜在生物标志物:健康受试者和帕金森病患者的差异
Biomarkers in Neuropsychiatry Pub Date : 2025-06-14 DOI: 10.1016/j.bionps.2025.100132
Pepijn P.N.M. Eijsvogel , Andriy A. Gorbenko , Dan F. Tardiff , Michelle Skupien , Ken Rhodes , Robert H. Scannevin , Yalcin Yavuz , Emilie M.J. van Brummelen , Brigitte Robertson , Philip H.C. Kremer , Geert Jan Groeneveld
{"title":"Fatty acids as potential biomarkers of stearoyl-CoA desaturase inhibition: Variation in healthy subjects and Parkinson's disease patients","authors":"Pepijn P.N.M. Eijsvogel ,&nbsp;Andriy A. Gorbenko ,&nbsp;Dan F. Tardiff ,&nbsp;Michelle Skupien ,&nbsp;Ken Rhodes ,&nbsp;Robert H. Scannevin ,&nbsp;Yalcin Yavuz ,&nbsp;Emilie M.J. van Brummelen ,&nbsp;Brigitte Robertson ,&nbsp;Philip H.C. Kremer ,&nbsp;Geert Jan Groeneveld","doi":"10.1016/j.bionps.2025.100132","DOIUrl":"10.1016/j.bionps.2025.100132","url":null,"abstract":"<div><div>This study aimed to assess the naturally occurring variation in plasma fatty acids in healthy subjects and Parkinson’s disease (PD) patients. Alpha-synuclein (aSyn) plays a major role in Parkinson’s disease. Inhibition of stearoyl-CoA desaturase (SCD) reduces levels of mono-unsaturated C16 and C18 fatty acids, which are involved in aSyn toxicity in vitro and in vivo. The ratio of mono-unsaturated to saturated fatty acids (fatty acid desaturase index (FA-DI)) in plasma after SCD-inhibition correlates with effects on brain FA-DI. However, the FA-DI normal values and the inter- and intra-day variation in PD-patients and healthy subjects is unknown. Ten PD-patients (54 –73 years) and ten age-matched healthy subjects were included. On three consecutive days, fatty acids fractions and concentrations were measured throughout the day. Outcomes are expressed as estimated mean, and the coefficient of variation (CV%) in percentage. For C16 FA-DI, the inter-subject CV% was 20.7 % in healthy subjects, and 37.7 % in PD-patients. The intra-subject CV% over days was 14.0 % in healthy subjects, and 14.2 % in PD-patients, and within days 5.1 % in healthy subjects, and 5.9 % in PD-patients. For C18 FA-DI, the inter-subject CV% was 14.8 % in healthy subjects, and 16.0 % in PD-patients. The intra-subject CV% over days was 11.0 % in healthy subjects, and 8.6 % in PD-patients, and within days 8.4 % in healthy subjects, and 6.7 % in PD-patients. The observed extent of variability in healthy subjects and PD-patients support C16 and C18 FA-DI as suitable biomarkers to demonstrate target engagement in plasma, of for example SCD-inhibitors, in both healthy subjects and PD-patients.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"13 ","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to “Football-related concussions and head impacts are associated with changes in retinal structure and signaling” [Biomark. Neuropsychiatry 10 (2024) 100091] “与足球有关的脑震荡和头部撞击与视网膜结构和信号的变化有关”[生物标记]的勘误表。神经精神病学10 (2024)100091]
Biomarkers in Neuropsychiatry Pub Date : 2025-06-01 DOI: 10.1016/j.bionps.2024.100118
Steven M. Silverstein , Jason Atlas , Mia Young , Lyvia Bertolace , Iwona Juskiewicz , Kian Merchant-Borna , Sarah Dermady , Yonatan Abrham , Kyle Green , Jeff Bazarian , Rajeev S. Ramchandran , Brian P. Keane
{"title":"Corrigendum to “Football-related concussions and head impacts are associated with changes in retinal structure and signaling” [Biomark. Neuropsychiatry 10 (2024) 100091]","authors":"Steven M. Silverstein ,&nbsp;Jason Atlas ,&nbsp;Mia Young ,&nbsp;Lyvia Bertolace ,&nbsp;Iwona Juskiewicz ,&nbsp;Kian Merchant-Borna ,&nbsp;Sarah Dermady ,&nbsp;Yonatan Abrham ,&nbsp;Kyle Green ,&nbsp;Jeff Bazarian ,&nbsp;Rajeev S. Ramchandran ,&nbsp;Brian P. Keane","doi":"10.1016/j.bionps.2024.100118","DOIUrl":"10.1016/j.bionps.2024.100118","url":null,"abstract":"","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100118"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum regarding missing disclosure statements of previously published articles 关于先前发表的文章缺少披露声明的勘误
Biomarkers in Neuropsychiatry Pub Date : 2025-06-01 DOI: 10.1016/j.bionps.2025.100127
{"title":"Erratum regarding missing disclosure statements of previously published articles","authors":"","doi":"10.1016/j.bionps.2025.100127","DOIUrl":"10.1016/j.bionps.2025.100127","url":null,"abstract":"","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100127"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144280910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GABA dysfunction in schizophrenia: The GABAA receptor as a potential therapeutic target 精神分裂症的GABA功能障碍:GABAA受体作为潜在的治疗靶点
Biomarkers in Neuropsychiatry Pub Date : 2025-05-23 DOI: 10.1016/j.bionps.2025.100130
Brandon L.M. Crotchett, Seth D. Reighard, Henry A. Nasrallah
{"title":"GABA dysfunction in schizophrenia: The GABAA receptor as a potential therapeutic target","authors":"Brandon L.M. Crotchett,&nbsp;Seth D. Reighard,&nbsp;Henry A. Nasrallah","doi":"10.1016/j.bionps.2025.100130","DOIUrl":"10.1016/j.bionps.2025.100130","url":null,"abstract":"<div><div>Schizophrenia is a complex psychiatric disorder characterized by debilitating positive, negative, and cognitive symptoms, whose etiology is traditionally attributed to dopamine dysregulation. While dopamine receptor antagonists effectively alleviate positive symptoms, they fail to address the persistent cognitive and negative symptom domains of disease. Growing evidence supports a broader neurobiological framework in which cortical excitation-inhibition (E/I) imbalance acts as an upstream contributor to dopaminergic dysregulation in schizophrenia, with the neurotransmitters gamma-aminobutyric acid (GABA) and glutamate playing a critical role in this homeostasis. Herein, we summarize such evidence, including preclinical findings from animal models of schizophrenia that support the role of GABAergic dysfunction in disease pathophysiology and validate the GABA<sub>A</sub> receptor as a promising therapeutic target. We review the potential of subtype-selective GABA<sub>A</sub> receptor modulators to restore E/I balance and improve symptoms currently resistant to antidopaminergic agents. Key challenges and considerations for the future development of these therapeutics are also discussed, emphasizing the importance of targeting E/I imbalance to better understand and treat the network-level dysfunction underlying schizophrenia.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multidimensional perspectives on (bio)markers: Linking clinical and biological insights across psychiatric disorders, supporting a transdiagnostic model (生物)标记物的多维视角:将精神疾病的临床和生物学见解联系起来,支持跨诊断模型
Biomarkers in Neuropsychiatry Pub Date : 2025-05-20 DOI: 10.1016/j.bionps.2025.100129
Dusan Hirjak
{"title":"Multidimensional perspectives on (bio)markers: Linking clinical and biological insights across psychiatric disorders, supporting a transdiagnostic model","authors":"Dusan Hirjak","doi":"10.1016/j.bionps.2025.100129","DOIUrl":"10.1016/j.bionps.2025.100129","url":null,"abstract":"<div><div>This editorial serves as an introduction to the Special Issue \"Biomarkers of Trans-Nosological Functional Domains\", offering an overview of its central themes and contributions.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100129"},"PeriodicalIF":0.0,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dimensions of psychosis in delirious and catatonic trauma critically Ill patients 精神错乱和紧张性创伤危重病人的精神病维度
Biomarkers in Neuropsychiatry Pub Date : 2025-05-08 DOI: 10.1016/j.bionps.2025.100128
Ming-Ray Xu , Trey W. McGonigle , Jinyuan Liu , Robert S. Dittus , Stephan Heckers , Pratik P. Pandharipande , Shawniqua Williams Roberson , Mayur B. Patel , E. Wesley Ely , Jo Ellen Wilson
{"title":"Dimensions of psychosis in delirious and catatonic trauma critically Ill patients","authors":"Ming-Ray Xu ,&nbsp;Trey W. McGonigle ,&nbsp;Jinyuan Liu ,&nbsp;Robert S. Dittus ,&nbsp;Stephan Heckers ,&nbsp;Pratik P. Pandharipande ,&nbsp;Shawniqua Williams Roberson ,&nbsp;Mayur B. Patel ,&nbsp;E. Wesley Ely ,&nbsp;Jo Ellen Wilson","doi":"10.1016/j.bionps.2025.100128","DOIUrl":"10.1016/j.bionps.2025.100128","url":null,"abstract":"<div><h3>Objective</h3><div>We examined the effect of delirium and catatonia on psychosis symptom presentation in trauma intensive care unit (TICU) patients without previous history of serious psychiatric illness.</div></div><div><h3>Design</h3><div>Prospective observational cohort study at a single academic medical center TICU, enrolling adult patients with critical illness secondary to traumatic injury excluding patients with significant psychiatric history. ICU patients received once-daily DSM-5 delirium and catatonia evaluations, and Clinician-Related Dimensions of Psychosis Severity Scale (CRDPSS) assessment. Patients were grouped by delirium and/or catatonia diagnosis with Kruskal-Wallis and Pearson’s Chi-square testing of differences between groups in CRDPSS scores.</div></div><div><h3>Main Results</h3><div>74 patients were sorted into delirium and/or catatonia groups for the dimensions of psychosis analysis. Catatonia was common in this critically ill trauma population with 26 % prevalence. Patients with delirium and/or catatonia diagnoses had differing severities of psychosis symptoms from those with neither condition. CRDPSS total scores were significantly different between the groups (p = 0.011).</div></div><div><h3>Conclusions</h3><div>Further investigation is needed to explore commonalities in the mechanisms underpinning ICU psychosis and to identify specific psychotic symptom manifestations suggestive of delirium versus catatonia.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143927533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic predictors of attempted suicide among South Indian adolescents and young adults: A case-control study 南印度青少年和年轻人自杀未遂的遗传预测因素:一项病例对照研究
Biomarkers in Neuropsychiatry Pub Date : 2025-03-26 DOI: 10.1016/j.bionps.2025.100126
Anju Mathew , Ann Mary Alex , Chathathayil Mohammedali Shafeeque , Saboora Beegum Muthubeevi , Vijayakumar Krishnapillai , Moinak Banerjee
{"title":"Genetic predictors of attempted suicide among South Indian adolescents and young adults: A case-control study","authors":"Anju Mathew ,&nbsp;Ann Mary Alex ,&nbsp;Chathathayil Mohammedali Shafeeque ,&nbsp;Saboora Beegum Muthubeevi ,&nbsp;Vijayakumar Krishnapillai ,&nbsp;Moinak Banerjee","doi":"10.1016/j.bionps.2025.100126","DOIUrl":"10.1016/j.bionps.2025.100126","url":null,"abstract":"<div><h3>Background</h3><div>Suicide among adolescents and young adults is an alarming public health issue globally. Though studies suggest the link between genetic factors and suicidal behavior, there is a paucity of studies of specific genetic variants in adolescents and young adults. Hence this study explored the genetic predictors for attempted suicide among adolescents and young adults, by studying the genetic basis of serotonin and dopamine synthesis, transport, and degradation machinery.</div></div><div><h3>Methods</h3><div>A Case-control association study was conducted comprising individuals with attempted suicide (cases n = 80), 13–29 years of age, belonging to Malayalam speaking Dravidian population, and attending a tertiary care center in South India. Age, sex, and ethnicity matched controls (n = 267) with no history of attempted suicide were also considered from the same ethnic population. Genotyping was performed for functionally critical SNP in serotonin receptor, Tryptophan hydroxylase, Tyrosine hydroxylase, and Catechol-o-methyl transferase. Statistical significance for allelic and genotypic comparisons and their odds ratios were computed.</div></div><div><h3>Results</h3><div>The Tyrosine Hydroxylase THrs2070762 and Tryptophan Hydroxylase TPH1rs211105 genetic variants showed a statistically significant association with attempted suicide phenotype.</div></div><div><h3>Conclusion</h3><div>The study suggests that the genetic variants in Tyrosine Hydroxylase and Tryptophan Hydroxylase are predictive of attempted suicide among adolescents and young adults. Understanding the genetic variations will help in identifying and managing high-risk individuals.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100126"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review of in vivo brain insulin resistance biomarkers in humans 人体内脑胰岛素抵抗生物标志物的系统综述
Biomarkers in Neuropsychiatry Pub Date : 2025-03-08 DOI: 10.1016/j.bionps.2025.100125
Graham Reid , Brendan Sargent , Sarah Bauermeister , Amanda Adler , Ivan Koychev
{"title":"A systematic review of in vivo brain insulin resistance biomarkers in humans","authors":"Graham Reid ,&nbsp;Brendan Sargent ,&nbsp;Sarah Bauermeister ,&nbsp;Amanda Adler ,&nbsp;Ivan Koychev","doi":"10.1016/j.bionps.2025.100125","DOIUrl":"10.1016/j.bionps.2025.100125","url":null,"abstract":"<div><div>Type 2 diabetes mellitus (T2DM) is associated with an elevated risk of dementia, prompting interest into the concept of brain-specific insulin resistance. However, the brain's reliance on insulin-independent glucose transporters complicates attempts to measure in vivo brain insulin resistance using the definition of system-wide insulin resistance, which is based on glucose-insulin interactions. In this review, we explore three available biomarkers for evaluating in vivo brain-specific insulin resistance in humans: (1) correlating systemic insulin resistance with brain function, (2) examining functional brain changes after the administration of intranasal insulin, and (3) quantifying insulin signalling proteins in neuronally enriched blood-derived extracellular vesicles. Integrating evidence from these three approaches tentatively suggests for the first time that a comprehensive assessment of the brain's default mode network (DMN), combining these methodologies within a single study, may offer a useful biomarker to quantify in vivo brain-specific insulin resistance in humans. Correlating DMN responses to concentrations of pY-IRS-1 in blood-derived extracellular vesicles would corroborate evidence for a brain-specific biomarker and provide a scalable approach to detecting brain-specific insulin resistance in humans. This advancement would enable in vivo evaluations of insulin resistance in the central nervous system, akin to the precise measurements of systemic insulin resistance seen in T2DM. An established and clearly defined biomarker of in vivo brain insulin resistance in humans would permit further investigation into the links between diabetes and dementia, ultimately bolstering support for secondary dementia prevention by identifying those at higher risk for cognitive decline.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100125"},"PeriodicalIF":0.0,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whole-body hyperthermia as a novel antidepressant therapy 全身热疗作为一种新的抗抑郁疗法
Biomarkers in Neuropsychiatry Pub Date : 2025-03-04 DOI: 10.1016/j.bionps.2025.100124
Kevin D. Gaitonde , Henry A. Nasrallah
{"title":"Whole-body hyperthermia as a novel antidepressant therapy","authors":"Kevin D. Gaitonde ,&nbsp;Henry A. Nasrallah","doi":"10.1016/j.bionps.2025.100124","DOIUrl":"10.1016/j.bionps.2025.100124","url":null,"abstract":"<div><div>First-line treatments for major depressive disorder include medication and cognitive behavioral therapy. While effective, pharmacotherapy often takes time to start demonstrating efficacy in symptomatic improvement and may be accompanied by adverse effects, indicating an ongoing need for new therapeutic approaches. A recently emerging somatic antidepressant intervention is whole-body hyperthermia, in which subjects are temporarily exposed to heat and then allowed to cool down. Recent studies employing hyperthermia-based strategies appear to show mood improvements both immediately and several weeks after the conclusion of treatment. However, published studies are often limited by their sample sizes and by their selection criteria. In this article, we review the literature on this novel approach and propose ideas regarding the possible physiological basis of this novel intervention and how it may be used in the future as adjunctive therapy with the current standard of care.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100124"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inducible HSP72 protein as a marker of neuronal vulnerability in brain research: A potential biomarker for clinical psychiatry? 诱导型HSP72蛋白作为脑研究中神经元易损性的标志物:临床精神病学的潜在生物标志物?
Biomarkers in Neuropsychiatry Pub Date : 2025-02-08 DOI: 10.1016/j.bionps.2025.100123
Ana-Maria Iorgu , Dragos Inta , Peter Gass
{"title":"Inducible HSP72 protein as a marker of neuronal vulnerability in brain research: A potential biomarker for clinical psychiatry?","authors":"Ana-Maria Iorgu ,&nbsp;Dragos Inta ,&nbsp;Peter Gass","doi":"10.1016/j.bionps.2025.100123","DOIUrl":"10.1016/j.bionps.2025.100123","url":null,"abstract":"<div><div>The aim of this review is to analyze the potential of the inducible form of 70-kDa heat shock protein (i.e. HSP72) as a biomarker for neuropsychiatric diseases, focusing on both animal and clinical studies. We first discuss findings from animal studies where HSP72 has already revealed its reliability as a sensitive marker of neuronal vulnerability, especially research investigating NMDAR antagonists-induced neurotoxicity, cerebral ischemia, epilepsy, behavioral stress, and effects of psychoactive and/or addictive substances. Next, we summarized human studies providing evidence for the involvement of HSP72 in the pathology of neuropsychiatric disorders like major depression, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, autism spectrum disorder, and neurodegenerative disorders. Finally, we discuss potential future research approaches needed to further investigate and possibly validate HSP72 as a biomarker in clinical psychiatry.</div></div>","PeriodicalId":52767,"journal":{"name":"Biomarkers in Neuropsychiatry","volume":"12 ","pages":"Article 100123"},"PeriodicalIF":0.0,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143428838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信